Seattle Children's Hospital Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2012
NCT01757964
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

David Suskind

Active Ingredients

Drugs in Phase 1 Trials (1)

human fecal microbiota (Reybota) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 1)

Colitis, Ulcerative (Phase 1)

Crohn Disease (Phase 1)

Inflammatory Bowel Diseases (Phase 1)

Intestinal Diseases (Phase 1)

Ulcer (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1